A Turning Point in Breast Cancer Treatment: Predicting and Delaying Drug Resistance
A significant breakthrough in breast cancer treatment has been achieved, offering new hope for patients and a more personalized approach to care. Italian researchers have identified key genetic mutations that influence how tumors evolve and become resistant to therapies. This discovery, published in the prestigious journal Nature on March 17, 2026, marks a historic step towards delaying drug resistance and improving treatment efficacy.
Unlocking the Genetic Code of Resistance
The research, conducted by a team at the Istituto Europeo di Oncologia, focused on identifying the molecular profile that causes resistance to drugs in breast cancer. The team, comprised of Emanuela Ferraro, Antonio Marra, and Luca Boscolo Bielo, discovered that certain inherited genetic mutations play a crucial role in this process. Specifically, mutations in genes like BRCA2 can predispose tumors to develop resistance.
“We have established a model for predicting the trajectories of drug resistance based on the patient’s genome configuration, demonstrating once again the fundamental importance of knowing the genetic profile before treatment, to choose the best possible therapy for each person,” explains Antonio Marra.
The Role of BRCA2 and RB1
The study revealed a “double-hit” mechanism in tumors with BRCA2 mutations. These tumors are prone to losing the function of the RB1 gene, leading to DNA instability. This instability makes standard treatments, such as a combination of endocrine therapy and CDK4/6 inhibitors, less effective.
However, the research also identified a potential solution: PARP inhibitors. These drugs appear to be more effective in treating tumors with BRCA2 mutations, suggesting a new approach to treatment sequencing.
PARP Inhibitors: A Shift in Treatment Strategy
Currently, PARP inhibitors are typically used as a second-line treatment, after initial therapies have failed. However, the new findings suggest that prioritizing PARP inhibitors for patients with BRCA2 mutations could intercept the loss of RB1 function and delay the development of resistance. A study is already underway to explore this new strategy.
“PARP inhibitors have been used with excellent results against HER2-negative and BRCA1/2 mutated breast cancer, both metastatic and early stage. However, these excellent drugs have only been used in second line, i.e. When the first drug has stopped being effective. Our new data indicate instead that prioritizing Parp inhibitors in patients carrying the BRCA2 mutation, can intercept the trajectories of loss of the gene RB1 and thus delay resistance to drugs,” continues Antonio Marra.
Germline vs. Somatic Mutations: Understanding the Complexity
The study highlights the importance of considering both germline (inherited) and somatic (acquired) mutations in understanding drug resistance. Even as both types of mutations contribute to tumor evolution, the research clarifies how these genetic alterations interact to influence treatment outcomes.
Implications for Personalized Medicine
This research paves the way for a more personalized approach to breast cancer treatment. By analyzing a patient’s genetic profile, doctors can predict their likelihood of developing drug resistance and tailor their treatment plan accordingly. This could involve selecting different drugs, adjusting dosages, or incorporating PARP inhibitors earlier in the treatment process.
Frequently Asked Questions
- What are germline mutations? These are genetic changes inherited from parents that are present in all cells of the body.
- What are somatic mutations? These are genetic changes that occur during a person’s lifetime and are present only in tumor cells.
- What is the role of BRCA2 in breast cancer? Mutations in the BRCA2 gene can increase the risk of developing breast cancer and can also contribute to drug resistance.
- What are PARP inhibitors? These are drugs that block the PARP enzyme, which is involved in DNA repair. They are particularly effective in treating tumors with BRCA1/2 mutations.
Did you know? Over 5,800 patients were included in the clinical-genomic analysis that led to these groundbreaking findings.
Pro Tip: Genetic testing can help identify inherited mutations that may increase your risk of breast cancer and influence treatment decisions. Talk to your doctor about whether genetic testing is right for you.
This research represents a significant step forward in the fight against breast cancer. By understanding the genetic mechanisms that drive drug resistance, we can develop more effective and personalized treatments that improve outcomes for patients.
Desire to learn more? Explore additional resources on breast cancer research and treatment options here.
